

Seroquel™ (quetiapine) Clinical Trial report summaries

Search

Go

Home

Clinical trials

- Accolate™ (zafirlukast)
- Arimidex™ (anastrozole)
- Atacand™ (candesartan cilexetil)
- Casodex™ (bicalutamide)
- Crestor™ (rosuvastatin)
- Diprivan™ (propofol)
- Entocort™ (budesonide)
- Exanta™ (ximelagatran)
- Faslodex™ (fulvestrant)
- Iressa™ (gefitinib)
- Losec™ (omeprazole)
- Merrem™ (meropenem)
- Naropin™ (ropivacaine)
- Nexium™ (esomeprazole)
- Oxis™ (formoterol)
- Plendil™ (felodipine)
- Products in Development
- Pulmicort™ (budesonide)
- Rhinocort™ (budesonide)
- Selcken ZOK/Toprol-XL™ (metoprolol CR/XL)
- Seroquel™ (quetiapine)
 - Ongoing Studies
 - Symbicort™ (budesonide/formoterol)
 - Zoladex™ (goserelin acetate)
 - Zomig™ (zolmitriptan)

Glossary

Contact us

Sitemap

Seroquel™ (quetiapine) was first approved in 1997 for schizophrenia. Since the formation of AstraZeneca, Seroquel™ (quetiapine) has received approval for bipolar mania.

Please consult the prescribing information for the country concerned for guidance on the approved use of Seroquel™ (quetiapine).

Study Number	Completed Clinical Trial Report Summaries
50771L/0039	A Multicenter, Double-blind Comparison of Efficacy and Safety of Seroquel™ (Quetiapine Fumarate), Haloperidol, and Placebo in the Treatment of Elderly Subjects Residing in Nursing Homes or Assisted Care Facilities and Presenting with Alzheimer's Dementia and Psychoses or Other Selected Psychoses
50771L/0050	A Multicentre, Double-blind, Randomised Trial to Compare the Effects of Quetiapine and Haloperidol Treatment Strategies on Treatment Outcomes (50771L/0050[ESTO])
50771L/0099	A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania
50771L/0100	An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania
50771L/0104	An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) and Haloperidol as Monotherapy in the Treatment of Acute Mania
50771L/0105	An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania
5077US/0043	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) and Risperidone (RISPERDAL™) in the Treatment of Patients with Schizophrenia
5077US/0046	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) and Placebo in the Treatment of Agitation Associated with Dementia
5077US/0049	A Multicenter, Double-blind, Randomized, Placebo-controlled, Double-dummy Trial of the Use of Quetiapine Fumarate (Seroquel™) in the Treatment of Patients with Bipolar Depression
D1447C00135	A Confirmatory Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Use of Quetiapine Fumarate (Seroquel™) in the Treatment of Patients with Bipolar Depression.
D1444C00132	A 6-week, International, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.

Advanced search

Corporate Responsibility


- Bioethics Policy
- Code of Conduct

Quick links - Products

- Accolate™ (zafirlukast)
- Arimidex™ (anastrozole)
- Atacand™ (candesartan cilexetil)
- Casodex™ (bicalutamide)
- Crestor™ (rosuvastatin)
- Diprivan™ (propofol)
- Entocort™ (budesonide)
- Exanta™ (ximelagatran)
- Fasiodex™ (fulvestrant)
- Iressa™ (gefitinib)
- Losec™ (omeprazole)
- Merrem™ (meropenem)
- Naropin™ (ropivacaine)
- Nexium™ (esomeprazole)
- Oxis™ (formoterol)
- Products in Development
- Pulmicort™ (budesonide)
- Rhinocort™ (budesonide)
- Seroquel™ (quetiapine)
- Symbicort™ (budesonide/formoterol)
- Zoladex™ (goserelin acetate)
- Zomig™ (zolmitriptan)

Page tools

- Bookmark this site
- Bookmark this page
- Printer friendly
- Print this chapter



D1444C00133	A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.
5077IL/0041	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Patients With Schizophrenia.
D1441C00023	A Canadian, Multicentre, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment with Higher Doses of Quetiapine Fumarate (Seroquel™) greater than 800 mg/day in Schizophrenic or Schizoaffective Subjects.
D1441L00002	Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52 Week Comparison.
BU-5077-0011 (D1441L00028)	Trial results awaiting further analysis and interpretation. Anticipated posting date is March 2008. Comparison.
D1446L00002	A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) and Placebo in the Treatment of Agitation Associated with Dementia
5077IL/125	Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2008.
D1444C00004 (PRINCESS)	A 1-year, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase III Study to Evaluate Prevention of Relapse in Patients in Stable Condition with Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo.
D1444C00146	Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2008.
D1444C00147	A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release quetiapine Fumarate (SEROQUEL®) in Patients with Schizophrenia
D1447C00126	Trial results awaiting further analysis and interpretation. Anticipated posting date is June 2008. Comparison.
D1447C00127	Trial results awaiting further analysis and interpretation. Anticipated posting date is June 2008. Comparison.
D1441C00149	Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2009.

